VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2016

Feb 4, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2016-02-02

Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-02	Common Stock	A	17299	$0.01	Acquired	121763	Direct
2016-02-03	Common Stock	S	2597	$89.92	Disposed	119166	Direct
2016-02-03	Common Stock	S	2100	$90.98	Disposed	117066	Direct
2016-02-03	Common Stock	S	700	$91.89	Disposed	116366	Direct
2016-02-03	Common Stock	S	645	$92.80	Disposed	115721	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-02	Stock Option (Right to Buy)	$91.05	A	34482	Acquired	2026-02-01	Common Stock (34482)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $89.92 (range $89.31 to $90.27).

F3: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $90.98 (range $90.38 to $91.32).

F5: Open market sales reported on this line occurred at a weighted average price of $91.89 (range $91.38 to $92.35).

F6: Open market sales reported on this line occurred at a weighted average price of $92.80 (range $92.40 to $93.03).

F7: The option vests in 16 quarterly installments from 02/02/2016.